Dr. Eileen M O'Reilly, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Expert in Pancreatic Cancer
Studies Stomach Cancer
13 reported clinical trials
27 drugs studied
Area of expertise
1Pancreatic Cancer
Global LeaderStage IV
Stage III
ctDNA positive
2Stomach Cancer
Stage IV
Stage III
ctDNA positive
Affiliated Hospitals
Clinical Trials Eileen M O'Reilly, MD is currently running
Pertzye
for Pancreatic Cancer
The main purpose of this study is to see how pancrelipase affects the body mass index (BMI) in people with metastatic PDAC. BMI is a measure based on a person's height and weight. Other study goals are to explore two different dosing schedules of pancrelipase and to evaluate pancrelipase in people who do not have symptoms of EPI.
Recruiting1 award Phase 1 & 29 criteria
NALIRIFOX + Radiation
for Pancreatic Cancer
The researchers are doing this study to find out whether using the chemotherapy regimen NALIRIFOX in combination with ablative dose radiation therapy (AD-XRT) and the standard chemotherapy drug capecitabine is an effective treatment approach for people with locally advanced or borderline resectable pancreatic ductal adenocarcinoma (PDAC) before surgery. This type of treatment approach is called total neoadjuvant therapy (TNT). The researchers will also look at whether the sequence of the treatment approach (NALIRIFOX + ADXRT and capecitabine followed by surgery, when it is possible) is effective and causes few or mild side effects in participants. An important purpose of the study is to see how the study treatment (NALIRIFOX + AD-XRT and capecitabine) affects participants' quality of life. The researchers will measure quality of life by having participants fill out questionnaires
Recruiting1 award Phase 2
More about Eileen M O'Reilly, MD
Clinical Trial Related2 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Eileen M O'Reilly, MD has experience with
- Gemcitabine
- Nab-paclitaxel
- Durvalumab
- Stereotactic Ablative Body Radiotherapy (SABR)
- Pertzye
- Capecitabine
Breakdown of trials Eileen M O'Reilly, MD has run
Pancreatic Cancer
Stomach Cancer
Colorectal Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Eileen M O'Reilly, MD specialize in?
Eileen M O'Reilly, MD focuses on Pancreatic Cancer and Stomach Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are Stage III.
Is Eileen M O'Reilly, MD currently recruiting for clinical trials?
Yes, Eileen M O'Reilly, MD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Eileen M O'Reilly, MD has studied deeply?
Yes, Eileen M O'Reilly, MD has studied treatments such as Gemcitabine, Nab-paclitaxel, Durvalumab.
What is the best way to schedule an appointment with Eileen M O'Reilly, MD?
Apply for one of the trials that Eileen M O'Reilly, MD is conducting.
What is the office address of Eileen M O'Reilly, MD?
The office of Eileen M O'Reilly, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.